Drug-conjugated monoclonal antibodies for the treatment of cancer

Current Opinion in Pharmacology

Volumn 5, Issue 5 SPEC.ISS., 2005, Pages 543-549

  Lambert, John M ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; AURISTATIN E; AURISTATIN F; BB 10901; BMS 182248; CALICHEAMICIN DERIVATIVE; CANTUZUMAB MERTANSINE; CD22 ANTIBODY; CD30 ANTIBODY; CISPLATIN; CMB 401; DOLASTATIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN G4; LL 1; MAYTANSINE; MAYTANSINOID DERIVATIVE; METHOTREXATE; MLN 2704; MONOCLONAL ANTIBODY; RACHELMYCIN; RITUXIMAB; SB 408075; SGN 15; SGN 35; TAXOID; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ENZYME DEFECT; HUMAN; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 24344507278     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.04.017     Document Type: Review

References (56)

1. G. Kohler C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495-497
2. J.S. Ross D.P. Schenkein R. Pietrusko M. Rolfe G.P. Linette J. Stec N.E. Stagliano G.S. Ginsburg W.F. Symmans L. Pusztai G.N. Hortobagyi Targeted therapies for cancer Am J Clin Pathol 122 2004 598-609
3. W.A. Blättler R.V.J. Chari Drugs to enhance the therapeutic potency of anticancer antibodies: Antibody-drug conjugates as tumor-activated prodrugs In Anticancer Agents - Frontiers in Cancer Chemotherapy Edited by I. Ojima G.D. Vite K.H. Altmann 2001 American Chemical Society Washington 317-338
4. V.S. Goldmacher W.A. Blättler J.M. Lambert R.V.J. Chari Immunotoxins and antibody-drug conjugates for cancer treatment Edited by V. Muzykantov V. Torchilin Biomedical In Aspects of Drug Targeting 2002 Kluwer Academic Publishers Dordrecht 291-309
5. A.W. Tolcher S. Sugarman K.A. Gelmon R. Cohen M. Saleh C. Isaacs L. Young D. Healey N. Onetto W. Slichenmyer Randomized phase II study of BR96-Doxorubicin conjugate in patients with metastatic breast cancer J Clin Oncol 17 1999 478-484
6. H.D. King G.M. Dubowchik H. Mastalerz D. Willner S.J. Hofstead R.A. Firestone S.J. Lasch P.A. Trail Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains J Med Chem 45 2002 4336-4343
7. K. Ulbrich T. Etrych P. Chytil M. Jelinkova B. Rihova Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation J Drug Target 12 2004 477-489
8. J. Vega S. Ke Z. Fan S. Wallace C. Charsangavej C. Li Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly[L-glutamic acid] through a polyethylene glycol spacer Pharm Res 20 2003 826-832
9. G.L. Griffiths M.J. Mattes R. Stein S.V. Govindan I.D. Horak H.J. Hansen D.M. Goldenberg Cure of SCID mice bearing human B-lymphoma xenografts by and anti-CD74 antibody-anthracycline drug conjugate Clin Cancer Res 9 2003 6567-6571
10. H3] which exhibits rapid, high-level targeting of xenografts Cancer Res 56 1996 3055-3061
11. H.H. Sedlacek D. Seemann D. Hoffmann J. Czech P. Lorenz C. Kolar B. Bosslet Antibodies as Carriers of Cytotoxicity Edited by H. Huber W. Queisser In Contributions to Oncology 1992 Karger Basel 1-208
12. E.D. Lobo R.J. Hansen J.P. Balthasar Antibody pharmacokinetics and pharmacodynamics J Pharm Sci 93 2004 2645-2668
13. A.L. Smith K.C. Nicolaou The enediyne antibiotics J Med Chem 39 1996 2103-2117
14. P.F. Bross J. Beitz G. Chen X.H. Chen E. Duffy L. Kieffer S. Roy R. Sridhara A. Rahman G. Williams R. Pazdur Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin Cancer Res 7 2001 1490-1496
15. E.L. Sievers R.A. Larson E.A. Stadtmauer E. Estey B. Lowenberg H. Dombret C. Karanes M. Theobald J.M. Bennett M.L. Sherman et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244-3254
16. C.M. Zwaan D. Reinhardt S. Corbacioglu E.R. van Wering J.P.M. Bökkerink W.J.E. Tissing U. Samuelsson J. Feingold U. Creutzig G.J.L. Kaspers Gemtuzumab ozogamicin: First clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis Blood 101 2003 3868-3871
17. M. Buckwalter J.A. Dowell J. Korth-Bradley B. Gorovits P.R. Mayer Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia J Clin Pharmacol 44 2004 873-880
18. S. Amadori S. Suciu R. Willemze F. Mandelli D. Selleslag R. Stauder A. Ho C. Denzlinger G. Leone P. Fabris Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: A phase II study [AML-15] of the EORTC and GIMEMA leukemia groups Haematologica 89 2004 950-956
19. + primary resistant or relapsed acute myeloid leukemia Leuk Res 27 2003 893-897
20. F.J. Giles H.M. Kantarjian S.M. Kornblau D.A. Thomas G. Garcia-Moreno T.A. Waddelow C.L. David A.T. Phan D.E. Colburn A. Rashid E.H. Estey Mylotarg [gemtuzumab ozogamicin] therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 92 2001 406-413
21. M. Wadleigh P.G. Richardson D. Zahrieh S.J. Lee C. Cutler V. Ho E.P. Alyea J.H. Antin R.M. Stone R.J. Soiffer D.J. DeAngelo Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Blood 102 2003 1578-1582
22. I. Jedema R.M. Barge V.H. van der Velden B.A. Nijmeijer J.J. van Dongen R. Willemze J.H. Falkenburg Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: Rationale for efficacy in CD33-negative malignancies with endocytic capacity Leukemia 18 2004 316-325
23. R.B. Walter B.W. Raden D.M. Kamikura J.A. Cooper I.D. Bernstein Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity Blood 105 2005 1295-1302
24. M.L. Linenberger CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance Leukemia 19 2005 176-182
25. V.H. van der Velden N. Boeckx I. Jedema J.G. te Marvelde P.G. Hoogeveen M. Boogaerts J.J. van Dongen High C33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin [Mylotarg] treatment in acute myeloid leukemia patients Leukemia 18 2004 983-988
26. F. Lo-Coco G. Cimino M. Breccia N.I. Noguera D. Diverio E. Finolezzi E.M. Pogliani E. Di Bona C. Micalizzi M. Kropp et al. Gemtuzumab ozogamicin [Mylotarg] as a single agent for molecularly relapsed acute promyelocytic leukemia Blood 104 2004 1995-1999
27. P.P. Piccaluga G. Martinelli M. Rondoni M. Malagola S. Gaitani A. Isidori A. Bonini L. Gugliotta M. Luppi M. Morselli et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas Leuk Lymphoma 45 2004 1791-1795
28. J. Golay N. Di Gaetano D. Amico E. Cittera A.M. Barbui R. Giavazzi A. Biondi A. Rambaldi M. Introna Gemtuzumab ozogamicin [Mylotarg] has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo Br J Haematol 128 2005 310-317
29. S.Y. Chan A.N. Gordon R.E. Coleman J.B. Hall M.S. Berger M.L. Sherman C.B. Eten N.J. Finkler A phase 2 study of the cytotoxic immunoconjugate CMB-401 [hCTM01-calicheamicin] in patients with platinum-sensitive recurrent epithelial ovarian carcinoma Cancer Immunol Immunother 52 2003 243-248
30. P.R. Hamann L.M. Hinman C.F. Beyer L.M. Greenberger C. Lin D. Lindh A.T. Menendez R. Wallace F.E. Durr J. Upeslacis An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance Bioconjug Chem 16 2005 346-353
31. E.R. Boghaert L. Sridharan D.C. Armellino K.M. Khandke J.F. DiJoseph A. Kunz M.M. Dougher F. Jiang L.B. Kalyandrug P.R. Hamann et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts Clin Cancer Res 10 2004 4538-4549
32. J. DiJoseph D.C. Armellino E.R. Boghaert K. Kandke M.M. Dougher L. Sridharan A. Kunz P.R. Hamann B. Gorovits C. Udata et al. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies Blood 103 2004 1807-1814
33. T.W. Yu L. Bai D. Clade D. Hoffmann S. Toelzer K.Q. Trinh J. Xu S.J. Moss E. Leistner H.G. Floss The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum Proc Natl Acad Sci USA 99 2002 7968-7973
34. A.W. Tolcher L. Ochoa L.A. Hammond A. Patnaik T. Edwards C. Takimoto L. Smith J. de Bono G. Schwartz T. Mays et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study J Clin Oncol 21 2003 211-222
35. P.R. Helft R.L. Schilsky F.J. Hoke D. Williams H.L. Kindler E. Sprague M. DeWitte H.K. Martino J. Erickson L. Pandite et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors Clin Cancer Res 10 2004 4363-4368
36. Lambert JM, Howard M, Connors K, McCreery H, Rowinsky EK, Tolcher AW: Cantuzumab mertansine (SB-408075), a maytansinoid immunoconjugate directed to the CanAg antigen by the C242 antibody: Correlation of the pattern of CanAg expression by immunohistochemistry (IHC) with plasma CEA trends in patients with colorectal cancer in a phase I study. 39th Annual Meeting of ASCO, Chicago IL, May/June 2003. [Abstract #1495].
37. Lutz RJ, Xie H, Widdison WC, Wunderli PS, Steeves RM, Goldmacher VS, Lambert JM, Chari RVJ: HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. 96th Annual Meeting of AACR, Anaheim CA, April 2005. [Abstract #1429].
38. H. Xie C. Audette M. Hoffee J.M. Lambert W.A. Blättler Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine [huC242-DM1], and its two components in mice J Pharmacol Exp Ther 308 2004 1073-1082
39. N. Murray R. Salgia F.V. Fossella Targeted molecules in small cell lung cancer Semin Oncol 31 2004 106-111
40. + multiple myeloma cells Cancer Res 64 2004 4629-4636
41. N.H. Bander D.M. Nanus M.I. Milowsky L. KoSstakoglu S. Vallabahajosula S.J. Goldsmith Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen Semin Oncol 30 2003 667-676
42. M.D. Henry S. Wen M.D. Silva S. Chandra M. Nilton P.J. Worland A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer Cancer Res 64 2004 7995-8001
43. Glasky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin S, Morales A, Curley T, Delacruz A, Webb IJ, Scher HI: Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer. 40th Annual Meeting of ASCO, New Orleans LA, June 2004. [Abstract #4592].
44. Chari RVJ, Xie X, Leece BA, Garrett L, Mayo M, Whiteman K, Goldmacher VS, Lambert JM, Chakroun H, Bissery M-C, Hercend T, Lutz RJ: Preclinical evaluation of an anti-CD33-maytansinoid immunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia. 96th Annual Meeting of AACR, Anaheim CA, April 2005. [Abstract #LB-287].
45. S.O. Doronina B.E. Toki M.Y. Torgov B.A. Mendelsohn C.G. Cerveny D.F. Chace R.L. DeBlanc R.P. Gearing T.D. Bovee C.B. Siegall et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat Biotechnol 21 2003 778-784
46. J.A. Francisco C.G. Cerveny D.L. Meyer B.J. Mixan K. Klussman D.F. Chace S.X. Rejniak K.A. Gordon R. DeBlanc B.E. Toki et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102 2003 1458-1465
47. C.L. Law C.G. Cerveny K.A. Gordon K. Klussman B.J. Mixan D.F. Chace D.L. Meyer S.O. Doronina C.B. Siegall J.A. Francisco Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates Clin Cancer Res 10 2004 7842-7851
48. K.J. Hamblett P.D. Senter D.F. Chace M.M.C. Sun J. Lenox C.G. Cerveny K.M. Kissler S.X. Bernhardt A.K. Kopcha R.F. Zabinski et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin Cancer Res 10 2004 7063-7070
49. R.J. Sanderson M.A. Hering S.F. James M.M.C. Sun S.O. Doronina A.W. Siadak P.D. Senter A.F. Wahl In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate Clin Cancer Res 11 2005 843-852
50. A.M. Lillo C. Sun C. Gao H. Ditzel J. Parrish C.M. Gauss J. Moss B. Felding-Habermann P. Wirsching D.L. Boger K.D. Janda A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents Chem Biol 11 2004 897-906
51. S.C. Jeffrey M.Y. Torgov J.B. Andreyka L. Boddington C.G. Cerveny W.A. Denny K.A. Gordon D. Gustin J. Haugen T. Kline et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates J Med Chem 48 2005 1344-1358
52. M.L. Miller E.E. Roller R.Y. Zhao B.A. Leece O. Ab E. Baloglu V.S. Goldmacher R.V.J. Chari Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery J Med Chem 47 2004 4802-4805
53. E. Baloglu M.L. Miller E.E. Roller E.E. Cavanagh B.A. Leece V.S. Goldmacher R.V.J. Chari Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors Bioorg Med Chem Lett 14 2004 5885-5888
54. I. Ojima X. Geng X. Wu C. Qu C.P. Borella H. Xie S.D. Wilhelm B.A. Leece L.M. Bartle V.S. Goldmacher R.V.J. Chari Tumor-specific novel taxoid-monoclonal antibody conjugates J Med Chem 45 2002 5620-5623
55. X. Wu I. Ojima Tumor specific novel taxoid-monoclonal antibody conjugates Curr Med Chem 11 2004 429-438
56. H.D. King A.J. Staab K. Pham-Kaplita D. Yurgaitis R.A. Firestone S.J. Lasch P.A. Trail BR96 conjugates of highly potent anthracyclines Bioorg Med Chem Lett 13 2003 2119-2122